Huisheng Biotech announced that the company recently received a letter from its controlling shareholder, Wuhan Tongsheng Investment Co., Ltd., that its 2 million shares were released from the pledge on October 14, 2026, accounting for 2.42% of its shares and 0.99% of the company's total share capital. The pledgeholders were the Wuhan Wuchang Branch of Bank of Hubei Co., Ltd. After the pledge was lifted, Wuhan Tongsheng Investment Co., Ltd. held 82.8 million shares, with a shareholding ratio of 41.03%, and the remaining 2.1 million pledged shares, accounting for 2.54% of its shares and 1.04% of the company's total share capital. As of the disclosure date of the announcement, there is no risk of liquidation or compulsory transfer of the pledged shares held by the controlling shareholder, which will not lead to a change in the actual control of the company.

Huisheng Biotech announced that the company recently received a letter from its controlling shareholder, Wuhan Tongsheng Investment Co., Ltd., that its 2 million shares were released from the pledge on October 14, 2026, accounting for 2.42% of its shares and 0.99% of the company's total share capital. The pledgeholders were the Wuhan Wuchang Branch of Bank of Hubei Co., Ltd. After the pledge was lifted, Wuhan Tongsheng Investment Co., Ltd. held 82.8 million shares, with a shareholding ratio of 41.03%, and the remaining 2.1 million pledged shares, accounting for 2.54% of its shares and 1.04% of the company's total share capital. As of the disclosure date of the announcement, there is no risk of liquidation or compulsory transfer of the pledged shares held by the controlling shareholder, which will not lead to a change in the actual control of the company.